Head-To-Head Review: Oculis (OCS) vs. Its Rivals

Oculis (NASDAQ:OCS) is one of 896 public companies in the “Pharmaceuticals” industry, but how does it compare to its peers? We will compare Oculis to related businesses based on the strength of its dividends, risk, earnings, profitability, analyst recommendations, valuation and institutional ownership.

Earnings & Valuation

This table compares Oculis and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Oculis	$1.45 million	-$119.44 million	-4.38
Oculis Competitors	$3.54 billion	$3.17 billion	550.65

Oculis’ peers have higher revenue and earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Oculis and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oculis	1	0	9	0	2.80
Oculis Competitors	7792	13884	25777	1037	2.41

Oculis currently has a consensus target price of $38.89, indicating a potential upside of 419.21%. As a group, “Pharmaceuticals” companies have a potential upside of 25.92%. Given Oculis’ stronger consensus rating and higher possible upside, research analysts clearly believe Oculis is more favorable than its peers.

Institutional & Insider Ownership

22.3% of Oculis shares are owned by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 14.2% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Oculis and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oculis	-6,777.18%	-42.61%	-35.23%
Oculis Competitors	-2,372.59%	-220.82%	-15.99%

Risk and Volatility

Oculis has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Comparatively, Oculis’ peers have a beta of -3.70, suggesting that their average share price is 470% less volatile than the S&P 500.

Summary

Oculis peers beat Oculis on 8 of the 13 factors compared.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.